83% pCR: DESTINY-Breast11 Breaks the Neoadjuvant Ceiling

An anthracycline-free regimen delivering pCR rates this high was once unthinkable.

This clip breaks down the DESTINY-Breast11 efficacy data, including an 83% pCR rate in hormone receptor–negative disease and encouraging early event-free survival signals — raising the bar for neoadjuvant HER2-positive therapy.